Doctor Bio:
Dr. Xavier Leleu is Professor, Head of the Myeloma Clinic and Head of the Department of Haematology at Hôpital La Mileterie, part of the academic hospital of Poitiers (Centre Hospitalier Universitaire) in Poitiers, France.
Results of the IFM 2014-01 Study Presented at EHA 2022
Dr. Xavier Leleu Explains the Results of Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma Characterized with High-Risk Cytogenetics at EHA 2022
In this Video:
Dr. Xavier Leleu (Centre Hospitalier Universitaire—Poitiers, France) explains the results of the IFM 2014-01 Study of Ixazomib, Pomalidomide and dexamethasone (IxPd) in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics at EHA 2022
What is the purpose of the study?
In IFM 2010-02, Pomalidomide plus dexamethasone (Pd) in advanced high-risk relapsed/refractory multiple myeloma (HR RRMM) had demonstrated limited activity with no addition of a proteasome inhibitor (PI), and a good safety profile. Interestingly, there was a striking difference in time to progression (TTP), duration of response, and overall response rate (ORR) according to the presence of del(17p) compared with t(4;14) (TTP, 7.3 vs 2.8 months; duration of response, 8.3 vs 2.4 months; and ORR, 32% vs 15%).
The aim of the study is to determine the efficacy and safety profile of the association ixazomib, pomalidomide and dexamethasone HR RRMM
Conclusion:
The study IFM 2014-01 /IxPd in HR L2 RRMM met its primary end point objective since the median TTP was superior to 3 months, the median TTP reported in IFM2010-02 as a whole, with the addition of Ixazomib to Pomalidomide and dexamethasone in this population characterized with a very poor outcome. This data confirms the importance of proteasome inhibitors in HR RRMM. This phase 2 study needs confirmation in a larger cohort.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
